Cancer Clinical Trial
Official title:
The Effect of Continuing Medical Education (CME) on Early Cancer Diagnosis in General Practice
| Verified date | May 2017 |
| Source | University of Aarhus |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Background Denmark has a lower survival of cancer compared to most European countries. Fast
track pathways for organ specific cancers were established in the years 2008-2010. In 2011
further a fast track pathway for non-specific serious symptoms. Cancer in general practice
is a low prevalence condition. Each general practitioner (GP) will see 8-10 new cancer
patients per year. The investigators know that cancer patients have an increased use of
general practice prior to diagnosis and that 25% of them wait for more than 20 days in
general practice for referral according to the GPs. The latest Danish Cancer Plan therefore
includes a CME as a key strategy to lower the GP threshold to refer patients to cancer fast
track pathways.
The aim of this study was to investigate the effect of this CME in early cancer diagnosis.
This is measured by changes in GP knowledge, attitude and risk assessment. GP referral
behavior assessed by primary care interval and use of fast track referrals. GP´s cancer hit
rate, cancer patients´ tumor stage at treatment and 1 year survival.
Methods/Design The study is conducted as a stepped wedge controlled design based on a
quasi-cluster randomization.
In august 2012 an invitation to participate in the present study were sent to 859 general
Practitioners (GPs) from the Central Denmark Region. GPs completed a form for each patient
they referred to a fast-track diagnostic pathway for cancer within an 8-month period.
Every other week, we received data from a regional database. We reminded the referring
GP-practice about non included patients. The collected data will be linked to registries.
The CME-intervention The CME-course was a 3-hour meeting after work. Guided by the available
evidence from the literature following the investigators ensured a multifaceted interactive
teaching method including case-based education. The content included by other topics
positive predictive values, false reassurance from negative testing and other pit-false.
Statistical analyses The outcomes will be analyzed in a generalized linear random-effects
model with random effect of GPs. Based on data it will be assessed whether further modeling
of inter correlation within practices and within clusters is required, and whether the
intervention effects are assumed equal for all GPs, or in random interaction with them.
Analyses will be performed both in the full GP-population ("intention to intervening ") and
in the 3 subgroups of GPs.
| Status | Completed |
| Enrollment | 689 |
| Est. completion date | December 2016 |
| Est. primary completion date | December 2015 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: - GP should be a GP principal - The referring GP should complete the registration form - Patients should be referred directly from practice to hospital on cancer suspicion in the inclusion period September 2012- May 2013 Exclusion Criteria: - Patients already registered with one cancer, diagnosed within 5 years - Patients self-inflicted in delay |
| Country | Name | City | State |
|---|---|---|---|
| Denmark | Research Centre for Cancer Diagnosis in Primary Care, Research Unit for General Practice, Aarhus University | Aarhus | Aarhus C |
| Lead Sponsor | Collaborator |
|---|---|
| University of Aarhus | Danish College of General Practitioners, Danish Committee for Health Education |
Denmark,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | GP knowledge, attitude and likely behavior pre CME | GP knowledge and attitude are measured by ad hoc questions from an online questionaire. The answers will be dichotomized | Average 1 month before CME | |
| Other | Risk assessment | Risk assessment is measured as a risk of cancer (0%-100%) each time a GP refers a patient to a fast track pathway | 8 months | |
| Other | The concrete patient´s use of general practice half year prior to diagnosis | Patients use of general practice prior to diagnosis is measured as a ratio. The denominator is the amount of visits to general practice half year prior to diagnosis. The nominator is an average use of general practice over a half year based on the last years. The data is registered in health care registry. | 6 months | |
| Other | GP cancer hit rate | GP Cancer hit rate per is measured as a proportion between patients referred to a fast track pathway diagnosed with cancer related to the total amount of referred patients. Civil registration numbers of all referred patients per GP from the MedCom data will be merge with National Registry of Cancer (NRC). | 8 months | |
| Other | Tumor stage | Cancer patients´ tumor stage at treatment is measured by TNM-stage from Danish Cancer Registry. | 8 months | |
| Other | GP knowledge, attitude and likely behavior after CME | GP knowledge and attitude are measured by ad hoc questions from an online questionaire. The answers will be dichotomized | Average 7 months after CME | |
| Other | 1 year survival | Cancer patients´ 1 year survival is measured by merging their Civil Registration Numbers with the Cause of Death Register. | 1 year | |
| Primary | Primary care interval | Primary care interval is the amount of days from the date where the patient first presented a cancer relevant symptom to the GP to the date of referral to a fast track pathway for cancer. | 8 months | |
| Secondary | Use of fast track referrals | Use of fast track referrals is measured by counting the relevant electronic referral letters sent to a web interface called referral hotel (MedCom data) from each individual GP in Central Denmark Region. | 8 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
| Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
| Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
| Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
| Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
| Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
| Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
| Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
| Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
| Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
| Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
| Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
| Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
| Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
| Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|